Speech-Language Pathologists in Verona, NY Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Emily Rennie Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4937 Spring Rd, Verona, NY 13478 Phone: 315-361-5881

Courtney Sicilia Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4937 Spring Rd, Verona, NY 13478 Phone: 315-361-5500

Mrs. Colleen Patricia Smith, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5275 State Route 31, Verona, NY 13478 Phone: 315-829-2529    Fax: 315-829-5966

Mrs. Andrea Mary Connery, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4937 Spring Road, Madison Onelda Boces, Verona, NY 13478 Phone: 315-361-5902    Fax: 315-361-5653

Kelsey Froass Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5154 Hill Rd, Verona, NY 13478 Phone: 315-751-9236

News Archive

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects.

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

Chicago's poorest neighborhoods to experience demand for additional primary care doctors

Some of Chicago's poorest neighborhoods are expected to see the greatest demand for additional primary care doctors in 2014, as the Affordable Care Act boosts the number of newly insured patients seeking medical services, a new study has found.

Cancer Genomics now available online

Genome Research publishes online and in print today a special issue entitled, "Cancer Genomics," highlighting insights gained form cutting-edge genomic and epigenomic analyses of cancer.

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration, Inc. announced today that the success criteria for primary analysis of the Phase III Investigational New Drug study of the Biostat System were not met. The proportions of successful patients that received BIOSTAT BIOLOGX Fibrin Sealant or saline injection were not statistically significantly different when analyzed at the 26-week primary endpoint.

Read more Medical News

› Verified 9 days ago